Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
...was all the PI engagement, from the small, local Sirius, a ruse to get the project approval for Anglo American? Far fetched, but worth it for 100 years at 50% margin.
Not entirely convinced we'll get the 12 month data any time soon - the next hRPC milestone has been revised from 'Further Phase 2a data read-
outs in H1 2020' to 'Further data read-outs from
expanded Phase 2a study in
2020'.
No major changes from the last one:
http://www.reneuron.com/wp-content/uploads/ReNeuron-corporate-presentation-Jan-2020.pdf
With AA seemingly endorsing a potential EBITDA in excess of 50%, I'm struggling to see why there is an issue achieving suitable financing.
https://www.edisongroup.com/publication/a-transformational-year-2/25879
Regarding hRPC, Olav also mentioned that the improvement in some non-treated eyes may be liked to the improvement in the treated eye. If it is in some way a case of the treated helps the non-treated, imagine the boost that could be seen when both eyes are treated.
Have you all listened to the webcast? Very positive. Olav commented on the significant value that a positive Phase III CTX trial will unlock, and no concerns with the procedure-related vision loss in the small number of hRPC patients - essentially their retinas were already significantly damaged which made the surgery risky, but other trials, including Luxturna, have had the same or worse problems.
The only slight surprise for me being that interest from Japan is more around hRPC and exosomes than CTX.
'With initial flow rates already announced, short term rates being higher, and the coal seam still to become gas saturated, the Company is very confident that sustained commercial gas flows will be attained from the Lesedi pods.'
Based on water pump RPM figures, do we concur that short term gas flow rates of up to 80,000 cu. ft./day have been achieved? My assumption is that 80,000 cu. ft./day = 100 RPM, 100,000 = 63 RPM, 110,000 = 50 RPM.
Essentially, commercial flow rates have been achieved, they now need to be maintained, but that's almost guaranteed as there's still more water to be pumped.
The primary risk being that the water keeps coming.
A good overview I think, nothing new but when you look at the 2a data for both hRPC and CTX, it doesn't look bad.
Cone rod dystrophy trial could be added to the schedule at any time.
Current market cap of £42 mil. is lower than some similar business' pre-trial capital raises.
http://www.reneuron.com/wp-content/uploads/ReNeuron-corporate-presentation-Nov-2019.pdf
RENE_to_40p, if you watch the video I posted below, Michael Hunt has said they won't need a huge amount of cash to get BOTH products to market.
I'm fairly confident that if they get one to market, they'll be able to fund the other.
Approximately 50% of the current market cap is cash.
Michael Hunt:
https://youtu.be/NsKp92xLzVI
In my view Woodford didn't buy 30% here to sell on a licence deal, he bought to sell on a takeover. For as long as that remains a distinct possibility, I see no reason why he'd sell any considerable amount.
Subjects 1 and 2 had the lowest baseline at 9 letters.
Subject 3 baseline was 32 letters.
Subjects 4 to 12 baselines will be between 36 and 63 letters.
It's clear that subject 1 dropped off towards 9 months, but still a 13 letter difference between treated and untreated, and if the treatment interval is to be 12-monthly I would expect a drop-off towards the next intervention.